BioNotebook: Tesaro, Geron raise cash; Aveo, Astellas end tivozanib trial; OraMed's oral insulin data
This article was originally published in Scrip
Executive Summary
Investors had opposite reactions to stock offerings from Tesaro and Geron on 30 January, sending the former company's shares slightly down and giving the latter cancer drug developer's stock a big boost based on updated clinical trial data.